These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 27077314)

  • 1. Multilayer engineered nanoliposomes as a novel tool for oral delivery of lipopeptide-based vaccines against group A Streptococcus.
    Marasini N; Giddam AK; Ghaffar KA; Batzloff MR; Good MF; Skwarczynski M; Toth I
    Nanomedicine (Lond); 2016 May; 11(10):1223-36. PubMed ID: 27077314
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liposome-based intranasal delivery of lipopeptide vaccine candidates against group A streptococcus.
    Ghaffar KA; Marasini N; Giddam AK; Batzloff MR; Good MF; Skwarczynski M; Toth I
    Acta Biomater; 2016 Sep; 41():161-8. PubMed ID: 27063491
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lipid core peptide/poly(lactic-co-glycolic acid) as a highly potent intranasal vaccine delivery system against Group A streptococcus.
    Marasini N; Khalil ZG; Giddam AK; Ghaffar KA; Hussein WM; Capon RJ; Batzloff MR; Good MF; Skwarczynski M; Toth I
    Int J Pharm; 2016 Nov; 513(1-2):410-420. PubMed ID: 27659862
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Double adjuvanting strategy for peptide-based vaccines: trimethyl chitosan nanoparticles for lipopeptide delivery.
    Marasini N; Giddam AK; Khalil ZG; Hussein WM; Capon RJ; Batzloff MR; Good MF; Toth I; Skwarczynski M
    Nanomedicine (Lond); 2016 Dec; 11(24):3223-3235. PubMed ID: 27830630
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Group A Streptococcal vaccine candidate: contribution of epitope to size, antigen presenting cell interaction and immunogenicity.
    Zaman M; Chandrudu S; Giddam AK; Reiman J; Skwarczynski M; McPhun V; Moyle PM; Batzloff MR; Good MF; Toth I
    Nanomedicine (Lond); 2014 Dec; 9(17):2613-24. PubMed ID: 25529566
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bivalent mucosal peptide vaccines administered using the LCP carrier system stimulate protective immune responses against Streptococcus pyogenes infection.
    Schulze K; Ebensen T; Chandrudu S; Skwarczynski M; Toth I; Olive C; Guzman CA
    Nanomedicine; 2017 Nov; 13(8):2463-2474. PubMed ID: 28887213
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Role of Size in Development of Mucosal Liposome-Lipopeptide Vaccine Candidates Against Group A Streptococcus.
    Ghaffar KA; Marasini N; Giddam AK; Batzloff MR; Good MF; Skwarczynski M; Toth I
    Med Chem; 2016; 13(1):22-27. PubMed ID: 27449794
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intranasal administration is an effective mucosal vaccine delivery route for self-adjuvanting lipid core peptides targeting the group A streptococcal M protein.
    Olive C; Sun HK; Ho MF; Dyer J; Horváth A; Toth I; Good MF
    J Infect Dis; 2006 Aug; 194(3):316-24. PubMed ID: 16826479
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Highly Immunogenic Trimethyl Chitosan-based Delivery System for Intranasal Lipopeptide Vaccines against Group A Streptococcus.
    Marasini N; Ghaffar KA; Giddam AK; Batzloff MR; Good MF; Skwarczynski M; Toth I
    Curr Drug Deliv; 2017; 14(5):701-708. PubMed ID: 27440071
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral immunization of mice with engineered Lactobacillus gasseri NM713 strain expressing Streptococcus pyogenes M6 antigen.
    Mansour NM; Abdelaziz SA
    Microbiol Immunol; 2016 Aug; 60(8):527-32. PubMed ID: 27301486
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structure-activity relationship for the development of a self-adjuvanting mucosally active lipopeptide vaccine against Streptococcus pyogenes.
    Zaman M; Abdel-Aal AB; Fujita Y; Ziora ZM; Batzloff MR; Good MF; Toth I
    J Med Chem; 2012 Oct; 55(19):8515-23. PubMed ID: 22974133
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design of three-component vaccines against group A streptococcal infections: importance of spatial arrangement of vaccine components.
    Abdel-Aal AB; Zaman M; Fujita Y; Batzloff MR; Good MF; Toth I
    J Med Chem; 2010 Nov; 53(22):8041-6. PubMed ID: 21028828
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunization with a tetraepitopic lipid core peptide vaccine construct induces broadly protective immune responses against group A streptococcus.
    Olive C; Ho MF; Dyer J; Lincoln D; Barozzi N; Toth I; Good MF
    J Infect Dis; 2006 Jun; 193(12):1666-76. PubMed ID: 16703510
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A dual-adjuvanting strategy for peptide-based subunit vaccines against group A Streptococcus: Lipidation and polyelectrolyte complexes.
    Zhao L; Yang J; Nahar UJ; Khalil ZG; Capon RJ; Hussein WM; Skwarczynski M; Toth I
    Bioorg Med Chem; 2020 Dec; 28(24):115823. PubMed ID: 33120079
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intranasal vaccination with a lipopeptide containing a conformationally constrained conserved minimal peptide, a universal T cell epitope, and a self-adjuvanting lipid protects mice from group A streptococcus challenge and reduces throat colonization.
    Batzloff MR; Hartas J; Zeng W; Jackson DC; Good MF
    J Infect Dis; 2006 Aug; 194(3):325-30. PubMed ID: 16826480
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activity Relationship of Poly(ethylenimine)-Based Liposomes as Group A
    Jin S; Zhang J; Nahar UJ; Huang W; Alharbi NA; Shalash AO; Koirala P; Yang J; Kiong JJE; Khalil ZG; Capon RJ; Stephenson RJ; Skwarczynski M; Toth I; Hussein WM
    ACS Infect Dis; 2023 Aug; 9(8):1570-1581. PubMed ID: 37489053
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systemic immunization with streptococcal immunoglobulin-binding protein Sib 35 induces protective immunity against group: a Streptococcus challenge in mice.
    Okamoto S; Tamura Y; Terao Y; Hamada S; Kawabata S
    Vaccine; 2005 Sep; 23(40):4852-9. PubMed ID: 15990202
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peptide amphiphile micelles self-adjuvant group A streptococcal vaccination.
    Trent A; Ulery BD; Black MJ; Barrett JC; Liang S; Kostenko Y; David NA; Tirrell MV
    AAPS J; 2015 Mar; 17(2):380-8. PubMed ID: 25527256
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intranasal immunization with serum opacity factor (SOF) of Streptococcus pyogenes fails to protect mice against lethal mucosal challenge with a heterologous strain.
    Schulze K; Medina E; Guzmán CA
    Vaccine; 2006 Feb; 24(9):1446-50. PubMed ID: 16289766
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel platform technology for modular mucosal vaccine that protects against streptococcus.
    Zaman M; Ozberk V; Langshaw EL; McPhun V; Powell JL; Phillips ZN; Ho MF; Calcutt A; Batzloff MR; Toth I; Hill GR; Pandey M; Good MF
    Sci Rep; 2016 Dec; 6():39274. PubMed ID: 27976706
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.